title: Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice.
authors.forename: N
authors.initials: N
authors.lastname: Neven
authors.forename: M
authors.initials: M
authors.lastname: Vis
authors.forename: A E
authors.initials: AE
authors.lastname: Voskuyl
authors.forename: G J
authors.initials: GJ
authors.lastname: Wolbink
authors.forename: M T
authors.initials: MT
authors.lastname: Nurmohamed
authors.forename: B A C
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: W F
authors.initials: WF
authors.lastname: Lems
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D009894:Opportunistic Infections / Q000139:chemically induced; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab